Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Science
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
-
Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
-
Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
-
Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
-
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
Development Pipeline
Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Science
